New recombinant antihemophilic factor approved

Published: 2008-09-05 06:41:00

Updated: 2008-09-05 06:41:00

Green Cross Corporation said on September 3 that the Korea Food and Drug Administration approved its new recombinant DNA-derived clotting factor to treat people with hemophilia A.

This new antihemophilic human factor VIII product is the one produced without using additives derived from human ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK